DXB

9.84%

55.0¢ dimerix limited

Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-586

First 586 Last

Share
Profile

Follow
Owl vs Fox

6,434 Posts.

5274

25/09/20

14:34

Post #: 47631126
Share

Originally posted by SteadyEddie: ↑

Thanks for the detailed analysis OvF. As a medico I thought I'd jump in and clarify some things for others.
Facts so far -
In FSGS: Orphan Drug status for DMX- 200 in FSGS was gained in December 2015. The recent FSGS trial results announced 29 July showed that DMX-200 drug works is patients with deteriorating kidney function reducing the rate of albuminuria ( protein loss in the urine) by average 29%. The mechanism of action is thought to be reducing damaging levels of inflammation. The average starting level of proteinuria in this group was 411mg/mmol - remember this number.... If you can reduce proteinuria you can delay / prevent the need to go on dialysis at cost $100,000 per year. Having orphan drug status means potentially you can charge up to about $80,000 per year per patient for DMX-200. Multiply that by the 80,000 patients with FSGS in USA and you get big numbers. The recent diabetic trial doesn't change any of these numbers.
Looking at Diabetic kidney disease (DKD): inclusion criteria same as earlier trials proteinuria >30mg/mmol, overall result not significantly better than placebo. BUT - still positive result in those with more serious disease > 57mg/mmol (18% improvement). In previous studies only patients with much higher levels of proteinuria actually joined the trials but in this study there were a significant proportion with only mild disease. Thus it seems that it works in more serious disease only. This is consistent with the FSGS trial - remember the average 411mg/mmol entry level for patients - much higher than the DKD trial. This is useful information to proceed to the phase 3 trial - patients with mild disease will be excluded. The market is still huge for severe disease. Looking forward to reading the in depth analysis by researchers.

My conclusion - DMX-200 appears to be an effective anti-inflam agent in mod - severe kidney disease - but we still need confirmation with a larger phase 3 trial.

Covid: study yet to start for DMX-700 - similar mechanism of action to reduce excessive inflammation without side effects associated with steroids.

Expand

Hi Steady Eddie,

Thank you, great post! The only thing Dyeman is correct it’s DMX-200 being trialled in COVID-19. DMX-700 is still in pre-clinical, albeit for COPD.

Did you ever go & see Steady Eddie live? He was hilarious, went to his stand up shows a few times. Are you a surgeon, as I could see why you chose that Nic?

DXB Price at posting: 24.0¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

BRX

Belararox delineates another porphyry in Argentina at Tambo South

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

FHE

Frontier Energy achieves key milestone for Waroona energy project

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

EMD

Emyria's Empax Centre chosen for mental health clinical trial

SBW

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

RDN

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

STX

Strike Energy secures $153 million for Perth Basin gas projects

AML

Cultural heritage agreement puts Walford Creek exploration back on the map

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

There are more pages in this discussion • 42 more messages in this thread...

First 586 Last

Add DXB (ASX) to my watchlist

(20min delay)
Last 55.0¢		Change -0.060(9.84%)		Mkt cap ! $302.3M

Open	High	Low	Value	Volume
60.5¢	61.0¢	55.0¢	$2.309M	4.010M

Buyers (Bids)

No.	Vol.	Price($)
9	137019	55.0¢

Sellers (Offers)

Price($)	Vol.	No.
55.5¢	22500	1

View Market Depth

No.	Vol.	Price($)
6	130691	0.550
4	35536	0.545
8	158059	0.540
3	46869	0.535
6	173766	0.530

Price($)	Vol.	No.
0.555	22500	1
0.560	21428	1
0.565	45284	3
0.575	10268	1
0.585	41022	3

Last trade - 16.10pm 21/06/2024 (20 minute delay)

DXB (ASX) Chart

Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-586

Belararox delineates another porphyry in Argentina at Tambo South

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

Frontier Energy achieves key milestone for Waroona energy project

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

Emyria's Empax Centre chosen for mental health clinical trial

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

Strike Energy secures $153 million for Perth Basin gas projects

Cultural heritage agreement puts Walford Creek exploration back on the map

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-586

Top Stories

Belararox delineates another porphyry in Argentina at Tambo South

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

Frontier Energy achieves key milestone for Waroona energy project

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

Emyria's Empax Centre chosen for mental health clinical trial

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

Strike Energy secures $153 million for Perth Basin gas projects

Cultural heritage agreement puts Walford Creek exploration back on the map

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News